Published in Ann Gastroenterol on September 30, 2016
Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet (2010) 13.13
Incidence of adenocarcinoma among patients with Barrett's esophagus. N Engl J Med (2011) 8.62
Prevalence of Barrett's esophagus in the general population: an endoscopic study. Gastroenterology (2005) 5.77
Is there publication bias in the reporting of cancer risk in Barrett's esophagus? Gastroenterology (2000) 4.74
British Society of Gastroenterology guidelines on the diagnosis and management of Barrett's oesophagus. Gut (2013) 4.29
Clinical outcome in patients treated with endoscopic submucosal dissection for superficial Barrett's neoplasia. Endoscopy (2014) 4.26
Final results from 10 year cohort of patients undergoing surveillance for Barrett's oesophagus: observational study. BMJ (2000) 4.21
Protective association of aspirin/NSAIDs and esophageal cancer: a systematic review and meta-analysis. Gastroenterology (2003) 3.90
Risk of esophageal adenocarcinoma and mortality in patients with Barrett's esophagus: a systematic review and meta-analysis. Clin Gastroenterol Hepatol (2009) 3.66
Gastro-oesophageal reflux symptoms, oesophagitis and Barrett's oesophagus in the general population: the Loiano-Monghidoro study. Gut (2008) 2.79
Oesophageal cancer is an uncommon cause of death in patients with Barrett's oesophagus. Gut (1996) 2.75
Screening for Barrett's esophagus in colonoscopy patients with and without heartburn. Gastroenterology (2003) 2.59
The incidence of oesophageal adenocarcinoma in non-dysplastic Barrett's oesophagus: a meta-analysis. Gut (2011) 2.51
Esophageal adenocarcinoma in Barrett's esophagus after endoscopic ablative therapy: a meta-analysis and systematic review. Am J Gastroenterol (2009) 2.46
Preoperative prevalence of Barrett's esophagus in esophageal adenocarcinoma: a systematic review. Gastroenterology (2002) 2.38
The incidence of esophageal cancer and high-grade dysplasia in Barrett's esophagus: a systematic review and meta-analysis. Am J Epidemiol (2008) 2.34
Oesophageal cancer incidence in the United States by race, sex, and histologic type, 1977-2005. Br J Cancer (2009) 2.33
Paired exome analysis of Barrett's esophagus and adenocarcinoma. Nat Genet (2015) 2.10
History, molecular mechanisms, and endoscopic treatment of Barrett's esophagus. Gastroenterology (2010) 2.05
Whole-genome sequencing provides new insights into the clonal architecture of Barrett's esophagus and esophageal adenocarcinoma. Nat Genet (2015) 1.89
Evaluation of a minimally invasive cell sampling device coupled with assessment of trefoil factor 3 expression for diagnosing Barrett's esophagus: a multi-center case-control study. PLoS Med (2015) 1.74
Risk of malignant progression in patients with Barrett's oesophagus: a Dutch nationwide cohort study. Gut (2010) 1.68
Gastric acid suppression and risk of oesophageal and gastric adenocarcinoma: a nested case control study in the UK. Gut (2006) 1.67
Non-steroidal anti-inflammatory drugs and risk of gastric and oesophageal adenocarcinomas: results from a cohort study and a meta-analysis. Br J Cancer (2009) 1.61
Central adiposity is associated with increased risk of esophageal inflammation, metaplasia, and adenocarcinoma: a systematic review and meta-analysis. Clin Gastroenterol Hepatol (2013) 1.56
Barrett's esophagus is common in older men and women undergoing screening colonoscopy regardless of reflux symptoms. Am J Gastroenterol (2006) 1.53
Medications (NSAIDs, statins, proton pump inhibitors) and the risk of esophageal adenocarcinoma in patients with Barrett's esophagus. Gastroenterology (2010) 1.51
Meta analysis: Cancer risk in Barrett's oesophagus. Aliment Pharmacol Ther (2007) 1.50
Grading of dysplasia in Barrett's oesophagus: substantial interobserver variation between general and gastrointestinal pathologists. Histopathology (2007) 1.47
Familial clustering of Barrett's esophagus and esophageal adenocarcinoma in a European cohort. Clin Gastroenterol Hepatol (2014) 1.46
Health benefits and cost effectiveness of endoscopic and nonendoscopic cytosponge screening for Barrett's esophagus. Gastroenterology (2012) 1.37
Predictors of progression in Barrett's esophagus: current knowledge and future directions. Am J Gastroenterol (2010) 1.35
Statins are associated with reduced risk of esophageal cancer, particularly in patients with Barrett's esophagus: a systematic review and meta-analysis. Clin Gastroenterol Hepatol (2013) 1.29
Association between markers of obesity and progression from Barrett's esophagus to esophageal adenocarcinoma. Clin Gastroenterol Hepatol (2013) 1.29
Nonsteroidal anti-inflammatory drugs and statins have chemopreventative effects in patients with Barrett's esophagus. Gastroenterology (2011) 1.25
Distribution and significance of epithelial types in columnar-lined esophagus. Am J Surg Pathol (2001) 1.22
BOB CAT: A Large-Scale Review and Delphi Consensus for Management of Barrett's Esophagus With No Dysplasia, Indefinite for, or Low-Grade Dysplasia. Am J Gastroenterol (2015) 1.17
Association between Helicobacter pylori and Barrett's esophagus, erosive esophagitis, and gastroesophageal reflux symptoms. Clin Gastroenterol Hepatol (2013) 1.09
A multibiomarker risk score helps predict risk for Barrett's esophagus. Clin Gastroenterol Hepatol (2013) 1.07
The effect of antireflux surgery on esophageal carcinogenesis in patients with barrett esophagus: a systematic review. Ann Surg (2007) 1.00
Barrett's oesophagus: epidemiology, cancer risk and implications for management. Gut (2013) 1.00
Regular statin and aspirin use in patients with Barrett's oesophagus is associated with a reduced incidence of oesophageal adenocarcinoma. Eur J Gastroenterol Hepatol (2012) 0.95
Epidemiology of symptom-defined gastroesophageal reflux disease and reflux esophagitis: the systematic investigation of gastrointestinal diseases in China (SILC). Scand J Gastroenterol (2010) 0.94
Cyclooxygenase inhibitors use is associated with reduced risk of esophageal adenocarcinoma in patients with Barrett's esophagus: a meta-analysis. Br J Cancer (2014) 0.92
Use of statin medications and risk of esophageal adenocarcinoma in persons with Barrett's esophagus. Cancer Epidemiol Biomarkers Prev (2012) 0.92
Combinatorial chemoprevention reveals a novel smoothened-independent role of GLI1 in esophageal carcinogenesis. Cancer Res (2010) 0.91
Barrett oesophagus: lessons on its origins from the lesion itself. Nat Rev Gastroenterol Hepatol (2014) 0.90
Improving surveillance for Barrett's oesophagus: AspECT and BOSS trials provide an evidence base. BMJ (2006) 0.89
Barrett's Esophagus: A Comprehensive and Contemporary Review for Pathologists. Am J Surg Pathol (2016) 0.88
Barrett's esophagus. Semin Gastrointest Dis (1996) 0.88
Quality of Barrett's surveillance in The Netherlands: a standardized review of endoscopy and pathology reports. Eur J Gastroenterol Hepatol (2008) 0.88
Validation of the Prague C&M classification of Barrett's esophagus in clinical practice. Endoscopy (2013) 0.82
Role of aspirin in chemoprevention of esophageal adenocarcinoma: a meta-analysis. J Dig Dis (2013) 0.82
Embryological signaling pathways in Barrett's metaplasia development and malignant transformation; mechanisms and therapeutic opportunities. Crit Rev Oncol Hematol (2014) 0.80
NSAIDs, statins, low-dose aspirin and PPIs, and the risk of oesophageal adenocarcinoma among patients with Barrett's oesophagus: a population-based case-control study. BMJ Open (2015) 0.80
Statins and aspirin for chemoprevention in Barrett's esophagus: results of a cost-effectiveness analysis. Cancer Prev Res (Phila) (2013) 0.77
Intestinal metaplasia in Barrett's oesophagus: An essential factor to predict the risk of dysplasia and cancer development. Dig Liver Dis (2015) 0.77